Refractory Fallopian Tube Carcinoma

8 clinical trials · Condition

Record	Firm	Date
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04753216)	Northwestern University	2021-03-16
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer (NCT04055649)	Ira Winer	2020-01-21
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (NCT04019288)	M.D. Anderson Cancer Center	2019-12-03
Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients (NCT04213794)	Mayo Clinic	2019-11-08
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (NCT03907527)	Precigen, Inc	2019-04-30
Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (NCT03026062)	M.D. Anderson Cancer Center	2017-05-18

Every clearance here is in the API, with alerts when new ones post.